Pharmacological inhibition of BET proteins using small-molecule inhibitors, such as JQ1 and I-BET762, has demonstrated promising therapeutic potential in preclinical models of cancer and fibrotic disorders [14,15,16]. This evidence concerns the gene DNER and cancer.